• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Differences in predictors of 5‐year survival over a 10‐year period in two cohorts of elderly nursing home residents in Sweden
ConclusionsThe present results indicate a trend that individuals are older and frailer when admitted to NH and that survival time after admission has been shortened. Hence, the need of daily support and care has increased, irrespective of housing. Also, predictors of survival, possible to influence, have changed.
Source: Scandinavian Journal of Caring Sciences - February 4, 2016 Category: Nursing Authors: Märta Sund Levander, Anna Milberg, Nils Rodhe, Pia Tingström, Ewa Grodzinsky Tags: Empirical Studies Source Type: research

Differences in predictors of 5 ‐year survival over a 10‐year period in two cohorts of elderly nursing home residents in Sweden
ConclusionsThe present results indicate a trend that individuals are older and frailer when admitted to NH and that survival time after admission has been shortened. Hence, the need of daily support and care has increased, irrespective of housing. Also, predictors of survival, possible to influence, have changed.
Source: Scandinavian Journal of Caring Sciences - February 3, 2016 Category: Nursing Authors: M ärta Sund Levander, Anna Milberg, Nils Rodhe, Pia Tingström, Ewa Grodzinsky Tags: Empirical Studies Source Type: research

Effectiveness of the influenza vaccine in preventing admission to hospital and death in people with type 2 diabetes.
Authors: Vamos EP, Pape UJ, Curcin V, Harris MJ, Valabhji J, Majeed A, Millett C Abstract BACKGROUND: The health burden caused by seasonal influenza is substantial. We sought to examine the effectiveness of influenza vaccination against admission to hospital for acute cardiovascular and respiratory conditions and all-cause death in people with type 2 diabetes. METHODS: We conducted a retrospective cohort study using primary and secondary care data from the Clinical Practice Research Datalink in England, over a 7-year period between 2003/04 and 2009/10. We enrolled 124 503 adults with type 2 diabetes. Outcome me...
Source: Canadian Medical Association Journal - July 28, 2016 Category: Journals (General) Tags: CMAJ Source Type: research

Do statins interfere with the flu vaccine?
Statins are powerful, unusual, and, like El Niño and Tom Cruise, not well understood. Statins have a huge upside. They improve survival after heart attacks and lower the risk of recurrent strokes. They are also the only cholesterol-lowering medications that have been clearly shown to reduce heart attacks and deaths in high-risk patients without heart disease. In addition to reducing cholesterol, statins also lower levels of inflammation in the body. Reducing inflammation probably helps statins to prevent heart attack and stroke. However, evidence is emerging that these statin effects may also have a downside, hindering th...
Source: New Harvard Health Information - November 30, 2015 Category: Consumer Health News Authors: John Ross, MD, FIDSA Tags: Cold and Flu Drugs and Supplements Health Heart Health Vaccines flu vaccine statins Source Type: news

Needs of Internally Displaced Women and Children in Baghdad, Karbala, and Kirkuk, Iraq
Conclusions The vulnerability of this population is great, and the emotional trauma of multiple displacements, kidnapping and deaths from intentional violence is great. While some aid is reaching families, much more is needed. Though Iraq is a middle income country, reaching the IDPs in central Iraq will take much more in international assistance than is currently being received. Unfortunately, at this time of great need, assistance is being cut back throughout the region because of lack of funding.10 The local civil society organizations which have sprung up in many locations to assist IDPs, offer an avenue for targeting ...
Source: PLOS Currents Disasters - June 10, 2016 Category: Global & Universal Authors: Gilbert Burnham Source Type: research

Pneumonia in the Noninstitutionalized Older Population.
CONCLUSION: Pneumonia plays an important role in the medical care of non-institutionalized older people. With the aid of the predictors identified in this study, primary care physicians can identify patients at risk, smokers can gain additional motivation to quit, treatment compliance can be increased, and patients may become more willing to be vaccinated as recommended in the current guidelines. PMID: 27697144 [PubMed - in process]
Source: Deutsches Arzteblatt International - October 5, 2016 Category: Journals (General) Tags: Dtsch Arztebl Int Source Type: research

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

U.S. FDA Approves TECVAYLI ™ (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
HORSHAM, Pa., October 25, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) approved TECVAYLI™ (teclistamab-cqyv) for the treatment of adult patients with relapsed or refractory multiple myeloma, who previously received four or more prior lines of therapy, including a proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody.1 TECVAYLI™ is a first-in-class, bispecific T-cell engager antibody that is administered as a subcutaneous treatment.1 This off-the-shelf (or ready to use) therapy uses innovative science to ac...
Source: Johnson and Johnson - October 25, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news